Frontlight ResearchEarly access
CompletedNo phase
Mitochondrial Diseases - Long-read Genome and Transcriptome Sequencing in Cases Unresolved After Short-read Genomics
Key facts
- Who runs it
- University Hospital Tuebingen
- Where
- Germany1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 1 Mar 2019
- Ended
- 1 Feb 2025
- Type of study
- Interventional
- Treatments tested
- Next Generation Sequencing (NGS)
- Record updated
- 30 March 2025
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Unclear diagnosis Suspected genetic cause of the disease
Who cannot take part
- Missing informed consent of the patient/ legal guardian
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The MiDiSeq project will enroll 20 unresolved index patients with suspected mitochondrial disease prioritized for genomic analysis.
The group in the trial
- Mitochondrial diseaseOther group
Unresolved index patients with suspected mitochondrial disease
Treatment: Next Generation Sequencing (NGS)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 30 March 2025